| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 18 Jun 2025 | 9 Jun 2025 |
| Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2025 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday June 18 2025 at 5:00 PM in Companys Chennai Office to take on record the following matter: 1. New acquisition 2. New drug license for a Chennai office 3. Diversification by creating new subsidiary 4. Any other agenda with the permission of the chair Outcome of the Board Meeting and disclosure under Regulation 30 of SEBI(Listing Obligations & Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement dated on 18.06.2025) | ||
| Board Meeting | 30 May 2025 | 23 May 2025 |
| Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve 1. To consider and approve the audited financial results for the quarter and the year ended on 31st March 2025 pursuant to regulation 33 of SEBI (Listed Obligations and Disclosure Requirements) Regulations 2015; 2. To consider any other matter with the permission of the Chairman of the meeting. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 30th May 2025, inter-alia, considered and approved (As Per BSE Announcement Dated on: 30/05/2025) | ||
| Board Meeting | 14 Feb 2025 | 7 Feb 2025 |
| KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve This is to inform you that the meeting of the Board of Directors of the Company to be held on Friday 14th February 2025 at Registered Office at 05.00 p.m. to transact the business as given below: 1.To consider and approve Unaudited financial results for the quarter ending on 31st December 2024 along with Limited Review Report pursuant to regulation 33 of SEBI (Listed Obligations and Disclosure Requirements) Regulations 2015; 2.To consider any other matter with the permission of the Chairman of the meeting. With reference to the above captioned subject, we hereby informed you that the Board of Directors at their meeting held today i.e., 14th February 2025, Board Meeting commenced at 05:00 PM. concluded at 6:30 PM at the registered office of the company have considered and approved the following: (As Per Bse Announcement Dated on 14.02.2025) | ||
| Board Meeting | 4 Dec 2024 | 25 Nov 2024 |
| Inter alia to consider and approve the following matters: 1. To consider and approve proposal of fund raising by issue of equity shares or any other permitted mode, through Preferential Allotment/Private Placement / Convertible warrants basis to the Promoter /Non-Promoter / Public Category of investors in accordance with the provision of the Companies Act, 2013 and SEBI (Issue of Capital and Disclosure Requirements Regulation, 2018, as amended, subject to regulatory or statutory approvals as may be required including the approval of the shareholders of the Company. 2. Increase in Authorised Share Capital of the company from 2,00,00,000 shares to 3,00,00,000 of Rs. 10 each. 3. To Consider shifting of Registered office of the company from Shop 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh 452011to No.3, 1st Floor, Swaminathan Street, West Mambalam, Chennai - In Compliance of Regulation 30 of the SEBI (LODR) Regulations, 2015 - Outcome of Board Meeting held on December 4, 2024. (As per BSE Announcement Dated on 04/12/2024) | ||
| Board Meeting | 14 Nov 2024 | 7 Nov 2024 |
| KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve This is to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday 14th November 2024 at 5 PM in our Registered office to transact the business Unaudited Financial Result for the quarter and half year ended September 30, 2024 Under Regulation 33 of SEBI (LODR) Regulations, 2015 (As per BSE Announcement dated on 14/11/2024) | ||
| Board Meeting | 4 Nov 2024 | 21 Oct 2024 |
| KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2024 inter alia to consider and approve Board of Directors of Company will be held on Monday November 04 2024 at 5.00 P.M. to consider and evaluate proposal for raising of funds by the Company Out come of Board Meeting (As per BSE Announcement Dated on 04/11/2024) | ||
| Board Meeting | 2 Sep 2024 | 27 Aug 2024 |
| KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2024 inter alia to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday September 2nd 2024 at 5:00 PM to consider and approve. Board of Directors of the company was held today viz Monday, 2nd September 2024 at registered office at 5:00 P.M. and concluded at 8:00 P.M. (As Per BSE Announcement Dated on: 02/09/2024) | ||
| Board Meeting | 14 Aug 2024 | 7 Aug 2024 |
| Quarterly Results Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 14th August 2024, (As per BSE Announcement Dated on 14/08/2024) | ||
| Board Meeting | 12 Jul 2024 | 6 Jul 2024 |
| KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/07/2024 inter alia to consider and approve This is to inform you that the meeting of the Board of Directors of the Company in convened on Friday 12 July 2024 at 03.00 p.m. to transact the business as given below: 1. To consider and change the registered office of the Company within the local limits of city where the registered office of the company is presently situated; 2. To consider any other matter with the permission of the Chairman of the meeting. Note: The trading window for dealing in shares in the Company for all the promoters directors designated employees and the concerned connected persons has been closed till 48 hours of the announcement of the financial results. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 12th July 2024, inter-alia, considered and approved the following: 1. The Registered Office of the Company is shifted from 270 Shastri Market Indore, Indore, Indore, Madhya Pradesh, India, 452007 to 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh 452011. 2. The Corporate office of the Company where books of accounts are maintained is No.3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai, Tamil Nadu, 600033. The meeting of the Board of Directors of the Company commenced at 03.00 p.m. (IST) and concluded at 05:00 p.m. (IST). (As per BSE Announcement Dated on 12/07/2024) | ||
| Board Meeting | 5 Jul 2024 | 5 Jul 2024 |
| With regards to the captioned matter and pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that at the meeting of the Board of Directors of Kabra Drugs Limited held today i.e. Friday, July 5, 2024 at 5:15 P.M. and concluded at 6:00 P.M. at the registered office of the Company situated at Office no: Shop No. 270, Shastri Market, Indore, Madhya Pradesh, 452001. It discussed and approved the matter with respect to the issuance of 56,90,500 equity shares of face value Rs.10/- each of the Company to non-promoters on preferential basis under Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.